Skip to main content
SpringerLink
Log in

Long-Term Drug Treatment of GERD

Economic Issues for Formulary Decision Makers

  • Review Article
  • Published:
Disease Management & Health Outcomes

Abstract

Gastroesophageal reflux disease (GERD) is one of the most common disorders of the gastrointestinal tract. Clinical presentation can vary from simple heartburn to erosive esophagitis. Some patients require long-term, possibly life-long, therapy. The cost of treatment is substantial, as patients with moderate to severe disease are high consumers of healthcare resources. The goal of therapy is to control symptoms, and to prevent complications, at a reasonable and manageable cost. Formulary decision making is more complex than simply choosing between proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2RAs); more importantly, it involves choosing the most cost-effective treatment strategy for a patient population. Since there are no long-term prospective economic studies available on the management of GERD, modeling studies provide the primary source of data for decision makers. A critical review of selected studies found that conclusions can vary based on a number of factors. These include the severity of GERD in the population being modeled, effectiveness endpoints, costs (drug and nondrug), and the inclusion of anti-reflux surgery. Effectiveness variables used in these models are generally based on randomized control trials in which endoscopic findings are used to judge success. This differs from the management of symptoms, as is common in clinical practice. In addition, the selection of which randomized clinical trial is used to define effectiveness endpoints can have a significant effect on the outcome. Thus, generalizability of economic studies often limits their value to decision makers. Pharmaceutical manufacturers have funded most of the studies in this area. For formulary decision makers to apply long-term economic analysis to their clinical practice, a critical review of these analyses is essential. Economic analysis can be a supplement to rational clinical judgment and experience in formulary decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Locke GR, Talley NJ, Fett SL. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112(5): 1448–56

    Article  PubMed  Google Scholar 

  2. Bieszk N, Kale-Pradhan PB. The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free. Ann Pharmacother 1999; 33(5): 638–41

    Article  PubMed  CAS  Google Scholar 

  3. Galmiche JP, Bruley des Varannes S. Symptoms and disease severity in gastroesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201: 62–8

    Article  PubMed  CAS  Google Scholar 

  4. Sonnenberg A. Cost effectiveness of competing strategies to prevent or treat GORD-related dysphagia. Pharmacoeconomics 2000; 17(4): 391–401

    Article  PubMed  CAS  Google Scholar 

  5. Falk GW. Reflux disease and Barrett’s esophagus. Endoscopy 1999; 31(1): 9–16

    Article  PubMed  CAS  Google Scholar 

  6. De Vault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94(6): 1434–42

    Article  Google Scholar 

  7. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis: the Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107(5): 1305–11

    PubMed  CAS  Google Scholar 

  8. Wesdorp IC, Dekker W, Festen HP. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis: Dutch Esophagitis Study Group. Clin Ther 1997; 19(5): 1048–57

    Article  PubMed  CAS  Google Scholar 

  9. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333(17): 1106–10

    Article  PubMed  CAS  Google Scholar 

  10. Spechler S, Lee E, Ahnen D. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8

    Article  PubMed  CAS  Google Scholar 

  11. Levin TR, Schmittdiel JA, Kunz K, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997; 103(6): 520–8

    Article  PubMed  CAS  Google Scholar 

  12. Holzer SS, Juday TR, Joelsson B, et al. Determining the cost of gastroesophageal reflux disease: a decision analytic model. Am J Manag Care 1998; 4(10): 1450–60

    PubMed  CAS  Google Scholar 

  13. DeVault KR. Managed care issues in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6 (16 Suppl.): S871–5

    PubMed  CAS  Google Scholar 

  14. Lipsey RJ. Institutional formularies: the relevance of pharmacoeconomics analysis to formulary decisions. Pharmacoeconomics 1992; 1(4): 265–81

    Article  Google Scholar 

  15. Jacobs P, Bachynsky J, Baladi J. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1996; 8(3): 182–9

    Article  Google Scholar 

  16. Hillman AL, Schwartz JS, Pauly MV et al. Task force on principles for economic analysis of health care technology: economic analysis of health care technology. Ann Intern Med 1995; 122: 61–70

    Google Scholar 

  17. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1998

    Google Scholar 

  18. Mason J. The generalizability of pharmacoeconomic studies. Pharmacoecomics 1997; 11(6): 503–14

    Article  CAS  Google Scholar 

  19. Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci 1998; 1(2): 133–40

    Article  PubMed  CAS  Google Scholar 

  20. Dean BB, Siddique RM, Yamashita BD, et al. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm 2001; 58(14): 1338–48

    PubMed  CAS  Google Scholar 

  21. Ofman JJ, Yamashita BD, Siddique RM, et al. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care 2000; 6(8): 905–16

    PubMed  CAS  Google Scholar 

  22. Sonnenberg A, Inadomi JM, Becker LA. Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13(8): 1003–13

    Article  PubMed  CAS  Google Scholar 

  23. Goeree R, O’Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16(6): 679–97

    Article  PubMed  CAS  Google Scholar 

  24. Goeree R, O’Brien B, Blackhouse G, et al. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value Health 2002; 5(4): 312–28

    Article  PubMed  Google Scholar 

  25. Gerson LB, Robbins AS, Garber A, et al. A cost-effective analysis of prescribing strategies in the management of gastroesophageal reflux disease. Gastroenterology 2000; 95: 395–407

    CAS  Google Scholar 

  26. Stalhammar NO, Carlsson J, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics 1999; 16(5 Pt 1): 483–97

    Article  PubMed  CAS  Google Scholar 

  27. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997; 92(12): 2179–87

    PubMed  CAS  Google Scholar 

  28. Birbara C, Breiter J, Perdomo C, et al. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease, Rabeprazole Study Group. Eur J Gastroenterol Hepatol 2000; 12(8): 889–97

    Article  PubMed  CAS  Google Scholar 

  29. Thjodleifsson B, Beker JA, Dekkers C, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45(5): 845–53

    Article  PubMed  CAS  Google Scholar 

  30. Haque M, Wyeth JW, Stace NH, et al. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J 2000; 113(1110): 178–81

    PubMed  CAS  Google Scholar 

  31. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4(5): 348–61

    Article  PubMed  CAS  Google Scholar 

  32. Hill S, Andrew M, Henry D. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283(16): 2116–21

    Article  PubMed  CAS  Google Scholar 

  33. Inadomi JM. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoecomics 2002; 20(9): 565–76

    Article  Google Scholar 

  34. O’Connor JB, Provenzale D, Brazer S. Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am J Gastroenterol 2000; 95(12): 3356–64

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Kaiser Permanente Medical Care Program, Outcomes Research Group, Pharmacy Operations, 1800 Harrison Street, Suite 1301, Oakland, California, 94612, USA

    James Chan Pharm D, PhD

  2. Gastroenterology Department, Kaiser Permanente Medical Center, Walnut Creek, California, USA

    Theodore R. Levin

Authors
  1. James Chan Pharm D, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodore R. Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Chan Pharm D, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, J., Levin, T.R. Long-Term Drug Treatment of GERD. Dis-Manage-Health-Outcomes 12, 399–407 (2004). https://doi.org/10.2165/00115677-200412060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200412060-00007

Keywords

Search

Navigation